509 related articles for article (PubMed ID: 12154045)
1. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
2. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
3. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
Rodolfo M; Zilocchi C; Melani C; Cappetti B; Arioli I; Parmiani G; Colombo MP
J Immunol; 1996 Dec; 157(12):5536-42. PubMed ID: 8955204
[TBL] [Abstract][Full Text] [Related]
5. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
6. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12.
Tannenbaum CS; Wicker N; Armstrong D; Tubbs R; Finke J; Bukowski RM; Hamilton TA
J Immunol; 1996 Jan; 156(2):693-9. PubMed ID: 8543822
[TBL] [Abstract][Full Text] [Related]
7. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection.
Scharton-Kersten TM; Wynn TA; Denkers EY; Bala S; Grunvald E; Hieny S; Gazzinelli RT; Sher A
J Immunol; 1996 Nov; 157(9):4045-54. PubMed ID: 8892638
[TBL] [Abstract][Full Text] [Related]
8. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
9. Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo MP; Vagliani M; Spreafico F; Parenza M; Chiodoni C; Melani C; Stoppacciaro A
Cancer Res; 1996 Jun; 56(11):2531-4. PubMed ID: 8653692
[TBL] [Abstract][Full Text] [Related]
10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.
Vagliani M; Rodolfo M; Cavallo F; Parenza M; Melani C; Parmiani G; Forni G; Colombo MP
Cancer Res; 1996 Feb; 56(3):467-70. PubMed ID: 8564954
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
13. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
14. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
15. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
Ledda MF; Adris S; Bravo AI; Bover L; Carbone C; Paleolog E; Mordoh J; Chernajovsky Y; Podhajcer OL
Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):769-78. PubMed ID: 8832108
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
17. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.
Stoppacciaro A; Paglia P; Lombardi L; Parmiani G; Baroni C; Colombo MP
Eur J Immunol; 1997 Sep; 27(9):2375-82. PubMed ID: 9341783
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
20. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
